MDxHealth Launches Equity Offering

DURHAM, NC, and LIEGE, BELGIUM - April 4, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced the launch of an equity offering by means of a private placement to certain investors, with the intention to raise an amount of approximately € 6 million. The size of the placement may be increased, however. The board of directors has cancelled the preferential subscription right of the existing shareholders in the framework of this transaction.

Kempen & Co and Nomura Code Securities are acting as joint lead managers and joint bookrunners and ING Belgium acts as co-lead manager for the private placement, which shall be structured as an accelerated bookbuilding process to establish the offer price and final size of the placement. The accelerated bookbuilding process shall start with immediate effect and is expected, barring unforeseen circumstances to close on April 5, subject to acceleration or extension of the timetable.

The net proceeds of the private placement will be used, in order of priority (subject to the size of the placement), to accelerate product development in line with the new business strategy and to set up a CLIA laboratory and hire a sales and marketing team in the US.

The new shares will be admitted to listing and will be fungible with the existing shares on NYSE Euronext Brussels following their issuance and the publication of the approved listing prospectus. The company has requested the Financial Services and Markets Authority to suspend its shares from trading on NYSE Euronext Brussels and NYSE Euronext Amsterdam pending the placement. Trading in the stock is expected to resume following the publication of the results of the placement.

The company will announce the results of the offering as soon as possible after closing of the bookbuilding in a subsequent press release.

MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing for personalized medicine. The company's tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research center such as Johns Hopkins University and Memorial Sloan Kettering, and major European academic medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono, Pfizer, and other industry leaders. More information can be found on the Company website: www.mdxhealth.com or on twitter at the following address : www.twitter.com/mdxhealth.

For more information:

Dr. Jan Groen, CEO                         Hans Herklots

MDxHealth                                        Capricorn One

+32 4 364 20 70                                 +41 79 598 7149

Important information about forward-looking statements

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of MDxHealth, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale is not permitted or to any person or entity to whom it is unlawful to make such offer, solicitation or sale. This press release is not an offer of securities for sale into the United States, Canada, Australia or Japan.

The new shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "US Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration. The Company does not intend to register any portion of the placing in the United States or to conduct a public offering of securities in the United States.

2011-04-04 Launch ENG...